Compass pathways stock forecast.

Nikkei 225. 30,696.96. -0.95%. Negative. Source: LSEG - data delayed by at least 15 minutes. Get Compass Pathways PLC (CMPS.OQ) real-time stock quotes, news, price and financial information from ...WebCompare with up to 5 Stocks. On Monday 11/06/2023 the closing price of the COMPASS Pathways PLC (spons. ADRs) share was $6.05 on NAS. Compared to the opening price on Monday 11/06/2023 on NAS of ...WebDetailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The ...What happened. Compass Pathways ( CMPS 6.18%) saw its shares drop more than 22% on Tuesday. The biotech stock, which focuses on mental health treatment, closed at $43.06 on Monday, opened at $40. ...Web

Market Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ... Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ...Web

LONDON, May 03, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health ...

Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51%).Low. $35.00. Average. $71.83. Current Price. $60.31. Overview. Research & Ratings. Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume ...

Apr 26, 2021 · Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, continuing what has been a multi-day uptrend for CMPS stock.; CMPS stock is now up ...

I last covered the company for Seeking Alpha back in September 2021 when Compass' share price traded at $32.6 and its market cap was ~$1.4bn, and despite arguably making some significant progress ...

Stock Price Forecast. The 5 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 38.00, with a high estimate of 120.00 and a low estimate of 22.00. The median estimate represents a +488.24% increase from the last price of 6.46. Here are some of the best psychedelic sector stocks generating a buzz among investors: — Atai Life Sciences NV (ticker: ATAI) — GH Research PLC ( GHRS) — Compass Pathways PLC ( CMPS ...4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.The Compass Pathways Plc (CMPS) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $20.62, representing a +291.30% increase from the current price of $5.27. The highest analyst price target is $35.17, and the lowest is $6.0744.COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.93 -0.05 (-0.84%) At close: 04:00PM EST. 6.03 +0.10 (+1.69%) After hours: 07:53PM EST.

Based on the most recent data, CMPS has returned 5% so far this year. Meanwhile, stocks in the Medical group have lost about 16.7% on average. This means that COMPASS Pathways PLC Sponsored ADR is ...Get Compass Pathways PLC (CMPS.O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments.Wall Street Stock Market & Finance report, prediction for the future: You'll find the Compass Pathways Plc - ADR share forecasts, stock quote and buy / sell signals below. According to present data Compass Pathways Plc - ADR's CMPS shares and potentially its market environment have been in bearish cycle last 12 months (if exists). A high-level overview of COMPASS Pathways plc (CMPS) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.WebCompass Pathways has released the strongest evidence yet that psilocybin can improve outcomes in patients with treatment-resistant depression, linking its COMP360 candidate to a sharp improvement ...View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ.

Psychedelics biotech giant COMPASS Pathways (NASDAQ:CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select group ...Oct 18, 2023 · Current. -$0.61. 1 Month Ago. -$0.60. 3 Months Ago. -$0.65. COMPASS Pathways PLC ADR analyst estimates, including CMPS earnings per share estimates and analyst recommendations.

Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies, and are pioneering the development of a ... COMPASS Pathways plc (CMPS) NasdaqGS - NasdaqGS Real Time Price. Currency in USD. Follow. 2W 10W 9M. 5.93 -0.05 (-0.84%) At close: 04:00PM EST. 6.03 +0.10 …Nov 29, 2022 · That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ... Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. Detailed statistics for COMPASS Pathways plc (CMPS) stock, including valuation metrics, financial numbers, share information and more. ... Analyst Forecast. The average price target for CMPS is …WebAug 16, 2023 · The private placement is being conducted in accordance with applicable rules of the Nasdaq Stock Market LLC (“Nasdaq”) and was priced to satisfy the “Minimum Price” requirement (as defined ... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $47.0... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Rep...Find the latest COMPASS Pathways Plc - American CMPS analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating ...Web

Find the latest COMPASS Pathways plc (CMPS) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.

Atai bought another 619,095 Compass Pathways shares in recent days, taking its stake in the company from 19.4% to 20.8%. The new shares were bought at around $31 each, meaning Atai paid around $12 ...

May 11, 2023 · In the last 3 months, 5 analysts have offered 12-month price targets for Compass Pathways. The company has an average price target of $50.6 with a high of $120.00 and a low of $19.00. Below is a ... Compass Pathways stock indicated to open around $25.00, or 47% above the $17 IPO price. Sep. 18, 2020 at 10:17 a.m. ET by Tomi Kilgore. Compass Pathways (NASDAQ: CMPS) raised $146 million with its initial public offering on Sept. 18. While the IPO's price was set at $17, on the first day of trading, it opened at $23.40 and closed ...Still, Compass Pathways stock sank 16% in the stock market today. That's after tumbling 12% on Monday from an eight-month high. Compass also reported financial results for the third quarter.COMPASS Pathways Plc American Depository Shares (CMPS) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. LONDON, Aug. 16, 2023 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today ...See the latest Compass Pathways PLC ADR stock price (CMPS:XNAS), related news, valuation, dividends and more to help you make your investing decisions.WebMarket Activity. Funds + ETFs. Analyst ratings can be used in addition to other personal research work prior to making investment decisions. Do Not Sell My Personal Information (CA Residents Only ...COMPASS Pathways's market cap is currently ―. The company's EPS TTM is $-1.981; its P/E ratio is -2.86; COMPASS Pathways is scheduled to report earnings on March 4, 2024, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials. Dec 22. Sep 22.Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 10 and 11 and 12 If the stock moves up, then it will find resistance near these levels.Based on short-term price targets offered by six analysts, the average price target for COMPASS Pathways PLC Sponsored ADR comes to $48.67. The forecasts range from a low of $19.00 to a high...

First ever phase 3 program of psilocybin therapy globally scheduled to begin in 2022 . Compass Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the Phase 3 pivotal program design for COMP360 psilocybin therapy in …COMPASS Pathways is looking at the long-term effects of COMP360 in our phase 3 programme in treatment-resistant depression.” Manish Agrawal, MD, Chief Executive Officer, Sunstone Therapies, and the trial’s Principal Investigator, said: “This pioneering study is the first of its kind, conducted within a community hospital cancer center.4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.Instagram:https://instagram. upcoming stock dividendshow do you buy nike stocksre dividendi.bond rate Feb 7, 2023 · 3. Compass Pathways. Compass Pathways (CMPS 6.61%) isn't a large holding for Wood. The psychedelic stock makes up less than 1% of her Ark Genomic Revolution ETF's portfolio. However, Compass ... will tesla stock go down tomorrowcanadian national railroad Merck & Co., Inc. 101.68. -0.53. -0.52%. In this article, we discuss 10 best psychedelic stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Best ... best platform for active traders Compass Pathways PLC Follow Share $5.83 After Hours: $6.12 (4.97%) +0.29 Closed: Nov 21, 6:09:39 PM GMT-5 · USD · NASDAQ · Disclaimer search Compare to Mind Medicine (MindMed) Inc $2.68 MNMD2.55%... Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.Web